Application of bifidobacterium lactis BL-99 in improving intestinal bacterial infection resistance and intestinal immunity
By using Bifidobacter lactis BL-99 strain, the problem of difficulty in improving the intestinal bacterial infection resistance and immunity in the prior art was solved, and the adhesion of pathogenic bacteria and the production of inflammatory factors was significantly reduced, and the function of the intestinal barrier was improved. It has wide application prospects.
Patent Information
- Application Number
- CN202410478450.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-11-29
- Filing Date
- 2020-11-30
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively improve the resistance to intestinal bacterial infection and intestinal immunity, especially when facing pathogenic bacteria such as enterotoxic E. coli and enteropathic E. coli, it is difficult to effectively reduce their intestinal epithelial cells. Adhesion ability and inflammatory factors production.
BL-99 strain of Bifidobacterium lactis BL-99 has gastric acid and intestinal fluid resistance, which can significantly inhibit the adhesion of intestinal pathogens, improve intestinal barrier integrity, and reduce the production of inflammatory factor IP-10, for preparation and improvement of Composition of intestinal immunity.
It significantly reduces the adhesion ability of pathogenic bacteria to intestinal epithelial cells, improves intestinal barrier function, activates intestinal immunity, and prevents diarrhea and intestinal inflammation. It has a wide range of application prospects in food, drugs and feed.
Smart Images

Figure BDA0004801162540000052 
Figure BDA0004801162540000053 
Figure BDA0004801162540000071
Abstract
Description
[0001] The present invention is a divisional application with application number 202011369724.5, application date November 30, 2020, and invention name “Application of Bifidobacterium lactis BL-99 to enhance resistance to intestinal bacterial infection and intestinal immunity”. Technical Field
[0002] The invention relates to the technical field of microorganisms, and in particular to a new application of Bifidobacterium lactis BL-99 (preservation number CGMCC No. 15650) in improving resistance to intestinal bacterial infection and intestinal immunity. Background Art
[0003] Intestinal epithelial cells are the first barrier of the body against pathogens. The adhesion or invasion of pathogens on epithelial cells will stimulate intestinal epithelial cells to produce inflammatory factors or chemokines. Some soluble mediators can regulate the intestinal immune system or induce the innate immune response of cells. Appropriate immune response and good epithelial cell barrier function will help protect the host from infection by pathogens.
[0004] Probiotics refer to a class of live microorganisms that can benefit human health when consumed in sufficient quantities. As an important component of the intestinal microbiome, probiotics play an important role in human health, such as providing nutrition, synthesizing vitamins, helping digestion, promoting angiogenesis and intestinal nerve function. Summary of the invention
[0005] One object of the present invention is to provide a new use of Bifidobacterium lactis BL-99.
[0006] The present invention provides a Bifidobacterium lactis, which is named BL-99 in the present invention. The strain has been deposited in the China General Microbiological Culture Collection Center CGMCC (address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences) on April 26, 2018, and the classification name is: Bifidobacterium lactis; the deposit number is CGMCC No.15650. The Bifidobacterium lactis provided by the present invention has gastric acid resistance and intestinal fluid resistance. When treated in gastric acid solution with a pH of 2.5 for 30 minutes, the survival rate of live bacteria is more than 62%, and the survival rate of live bacteria is more than 61% after being treated for 2 hours; the survival rate of live bacteria is more than 70% after being treated in small intestinal fluid with a pH of 6.8 for 2 hours.
[0007] In the present invention, enterotoxigenic Escherichia coli ETECH10407 and enteropathogenic Escherichia coli EPEC O119 were used as pathogenic bacteria strains to induce in vitro intestinal infection to study the function of Bifidobacterium lactis BL-99 in enhancing intestinal immunity. Both types of E. coli are common pathogens, including infant diarrhea, traveler diarrhea, and in developing countries or areas with poor sanitation. ETEC H10407 is a more mature and commonly used model strain in experiments, and is also often used to evaluate the adhesion ability of probiotics to pathogens and inflammatory signaling pathways.
[0008] The present invention has found that the Bifidobacterium lactis BL-99 (i.e., the Bifidobacterium lactis with a preservation number of CGMCC No. 15650) strain has the effect of inhibiting the adhesion of intestinal pathogens, can significantly inhibit the adhesion of ETEC H1407 and EPEC O119 to Caco-2 cells, improve the integrity of the intestinal barrier, and has the effect of inhibiting the production of intestinal inflammatory factors, and can alleviate the inflammatory response caused by ETEC H10407.
[0009] Therefore, the present invention provides the use of Bifidobacterium lactis in preparing a composition for improving intestinal immunity, and the preservation number of the Bifidobacterium lactis is CGMCC No.15650.
[0010] According to a specific embodiment of the present invention, in the application of the present invention, the Bifidobacterium lactis is used to prepare the composition in the form of a solid or liquid bacterial preparation of live bacteria and / or dead bacteria.
[0011] According to a specific embodiment of the present invention, in the application of the present invention, the enhancement of intestinal immunity includes: enhancing resistance to intestinal bacterial infection, resisting invasion of pathogenic bacteria in the intestinal system, maintaining intestinal barrier function, and / or preventing diarrhea caused by pathogenic bacteria.
[0012] According to a specific embodiment of the present invention, in the application of the present invention, the enhancing of intestinal immunity includes: reducing the adhesion ability of pathogenic bacteria to intestinal epithelial cells, and / or reducing the release of inflammatory factor IP-10 by intestinal cells caused by pathogenic bacteria.
[0013] According to a specific embodiment of the present invention, in the application of the present invention, the application amount of the Bifidobacterium lactis is 1.0×10 3 CFU~1.0×10 12CFU / day, or 0.001 μg to 1000 mg / day in terms of bacterial weight. Preferably, the amount of Bifidobacterium lactis used is 10 7 CFU~10 11 CFU / day, or 10 μg to 100 mg / day in terms of bacterial weight. The amount of Bifidobacterium lactis used is 1.0×10 3 CFU~1.0×10 12 CFU / day, or 0.001 μg to 1000 mg / day in terms of bacterial weight.
[0014] According to a specific embodiment of the present invention, the composition may include a food composition, a feed composition or a pharmaceutical composition.
[0015] According to a specific embodiment of the present invention, the composition can be used in animals or humans. The composition can also include conventional material components in the field. For example, for a pharmaceutical composition, an appropriate amount of excipients can be included, and the excipients can be excipients, diluents, fillers, absorption enhancers, etc. For food compositions, the lactobacillus of the present invention can be produced according to the food containing lactobacillus in the prior art, and the composition can be in different forms according to the needs of the recipient. For example, powders, tablets, granulations, microcapsules, liquid preparations, etc.
[0016] In a specific embodiment of the present invention, the composition is a food composition, and the food can be a liquid beverage, a solid beverage, an oral liquid, a dairy product, a tablet or a capsule, for example, it can be a fermented dairy product (such as fermented milk, flavored fermented milk, fermented milk beverage, etc.), cheese, milk-containing beverage, probiotic solid beverage or milk powder, etc.
[0017] In another specific embodiment of the present invention, the composition is a feed composition. Other components in the feed composition can be selected with reference to conventional techniques in the field of probiotic feed.
[0018] In another specific embodiment of the present invention, the composition is a pharmaceutical composition. Other components in the pharmaceutical composition can be selected with reference to conventional techniques in the field of probiotic drugs.
[0019] In summary, the present invention provides a new use of Bifidobacterium lactis BL-99, which has the effects of significantly reducing the adhesion of pathogenic bacteria to intestinal epithelial cells, improving intestinal barrier function, and activating intestinal immunity. It can be used to prepare food, medicine, and feed with anti-infection, intestinal health and immune regulation, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The results of the determination of the viable count of Bifidobacterium lactis BL-99 are shown.
[0021] Figure 2 The results showed that Bifidobacterium lactis BL-99 inhibited the adhesion of enterotoxigenic Escherichia coli ETEC H10407 to Caco-2 (p<0.05).
[0022] Figure 3 The results showed that Bifidobacterium lactis BL-99 inhibited the adhesion of pathogenic Escherichia coli EPEC O119 to Caco-2 (p<0.001).
[0023] Figure 4 The results showed that Bifidobacterium lactis BL-99 could reduce the production of IP10 induced by enterotoxigenic E. coli ETEC H10407 (p<0.001).
[0024] Patented procedure for preservation of microorganisms:
[0025] Bifidobacterium lactis BL-99 of the present invention:
[0026] Deposit date: April 26, 2018;
[0027] Depository: China General Microbiology Center (CGMCC);
[0028] Address of the depository: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, Deposit Number: CGMCC No. 15650;
[0029] Classification name: Bifidobacterium lactis. DETAILED DESCRIPTION
[0030] In order to have a clearer understanding of the technical features, purposes and beneficial effects of the present invention, the following detailed description is now given in conjunction with specific embodiments and the technical solutions of the present invention. It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of the present invention. In the embodiments, the experimental methods without specifying specific conditions are conventional methods and conventional conditions well known in the art, or according to the conditions recommended by the instrument manufacturer.
[0031] Bifidobacterium lactis BL-99
[0032] The Bifidobacterium lactis BL-99 of the present invention is isolated from the intestinal tract of infants. The strain has been deposited in the China General Microbiological Culture Collection Center CGMCC (address: No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences) on April 26, 2018, and the classification name is Bifidobacterium lactis; the deposit number is CGMCC No.15650.
[0033] 1. Taxonomic characteristics of Bifidobacterium lactis BL-99
[0034] The results of the physical and chemical experiments are shown in Table 1.
[0035] Table 1
[0036] Experimental Project result Experimental Project result Gram stain Positive Carbohydrate Acid Production (Continued) Cell shape Rod-shaped, polymorphic Ribose + Spore formation - Trehalose - Catalase - Xylose + Oxidase - maltose + Growing in the air - lactose + Anaerobic growth + Raffinose + Carbohydrate acid production Sorbitol - Mannose - Melibiose + Melezitose - Galactose + fructose - Mannitol - Salicin + L-arabinose - Inulin - Sodium Gluconate - Cellobiose - sucrose + starch +
[0037] 2. Tolerance of Bifidobacterium lactis BL-99 to artificial gastric juice and intestinal juice
[0038] Bifidobacterium is a genus of bacteria that is generally not acid-resistant. In this example, the artificial gastric juice and intestinal juice tolerance of the Bifidobacterium lactis BL-99 of the present invention was tested. At the same time, the Bifidobacterium lactis BL-99, which is currently recognized in the field as having excellent acid resistance and can survive through the gastrointestinal tract, was used as the For comparison.
[0039] Test method: After culturing Bifidobacterium lactis BL-99 strain in MRS liquid medium at 37°C for 16 hours, centrifuge at 4°C and 2500 rpm for 10 minutes to collect the bacteria.
[0040] The strains to be tested were cultured in artificial gastric juice and artificial intestinal juice, and viable bacteria were counted and analyzed after treatment at 37°C for 0, 30 minutes, and 2 hours, and the acid resistance and intestinal fluid resistance of the strains were evaluated by the survival rate. Survival rate = (number of viable bacteria after treatment / number of viable bacteria at time 0) × 100%.
[0041] The survival rate test results of the strains in artificial gastric acid (pH2.5) are shown in Table 2. When BB-12 is treated in artificial gastric acid (pH2.5) for 30 minutes, the survival rate of live bacteria is 7.04%, and the survival rate of live bacteria is only 1.64% after being treated for 2 hours; while the survival rate of live bacteria of the Bifidobacterium lactis BL-99 of the present invention is 62.60% when being treated in artificial gastric acid (pH2.5) for 30 minutes, and the survival rate of live bacteria is 61.83% after being treated for 2 hours. It shows that the Bifidobacterium lactis BL-99 of the present invention has excellent gastric acid resistance and can smoothly pass through the stomach to reach the intestinal tract to play a probiotic role.
[0042] Table 2 Survival rate of strains in artificial gastric acid (pH 2.5)
[0043]
[0044] The results of the survival rate test of the strains in artificial intestinal fluid (pH 6.8) are shown in Table 3. The data show that the survival rate of BB-12 in artificial intestinal fluid (pH 6.8) for 2 hours is only 28.95%, while the survival rate of the Bifidobacterium lactis BL-99 in the present invention is 70.23% in artificial intestinal fluid (pH 6.8) for 2 hours. This shows that the Bifidobacterium lactis BL-99 in the present invention has excellent intestinal fluid resistance and can survive and colonize in the intestine.
[0045] Table 3 Survival rate of strains in artificial intestinal fluid (pH 6.8)
[0046]
[0047] 3. Virulence experiment and safety test of Bifidobacterium lactis BL-99
[0048] The Bifidobacterium lactis BL-99 of the present invention was inoculated into a BBL liquid culture medium and cultured anaerobically at 36±1°C for 48±2 hours. The number of live bacteria of Bifidobacterium lactis BL-99 in the culture medium was counted to be 3.7×10 8 cfu / mL, the original culture solution and 5-fold concentrated solution were orally administered to the test mice at 20.0mL / kg BW for 3 consecutive days and observed for 7 days. The experiment set up a control group of culture medium original solution and 5-fold concentrated solution. The experimental results showed that the BBL culture original solution and 5-fold concentrated solution group of Bifidobacterium lactis BL-99 had no statistically significant effect on the weight gain of mice compared with their respective control groups (p>0.05), and no toxic reactions or deaths were observed in the test mice.
[0049] The antibiotic sensitivity of Bifidobacterium lactis BL-99 was evaluated using the method of SN / T 1944-2007 "Determination of bacterial resistance in animals and their products". The evaluation results showed that Bifidobacterium lactis BL-99 was sensitive to Ampicillin, Penicillin G, Erythromycin, Chloramphenicol, Clindamycin, Vancomycin and Tetracycline. It meets the requirements of the European Food Safety Authority for the evaluation of edible bacteria resistance. Bifidobacterium lactis BL-99 does not contain exogenous antibiotic resistance genes and is safe for consumption.
[0050] 4. Determination of the number of viable bacteria of Bifidobacterium lactis BL-99 used in the examples
[0051] Bifidobacterium lactis BL-99 (preservation number: CGMCC No.15650) was selected by plate spreading method and stored in glycerol tubes at -80℃ after 16S identification. Before the experiment, the strain was cultured in MRS medium at 37℃. The culture medium was centrifuged to enrich the bacteria when it grew to the logarithmic phase. The number of live bacteria and bacterial activity were determined by fluorescence activated cell sorting (FACS). The results are shown in Figure 1 The number of live bacteria in each embodiment of the present invention is divided into 1×10 8 CFU / mL and 1×10 6 CFU / mL.
[0052] 5. Data Analysis in Examples
[0053] All data in the experiment were repeated at least 3 times, and the experimental results are expressed as mean ± standard deviation. SPSS17.0 software was used for data analysis (SPSS, Chicago, IL, USA). The significance analysis was performed using the LSD method for one-way analysis of variance. P-value < 0.05 was considered to be statistically significant. Significant differences were distinguished by: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. GraphPad Prism 5.0 was used for drawing.
[0054] Example 1. Determination of anti-adhesion ability
[0055] The co-culture method was used to investigate whether Bifidobacterium BL-99 has Caco-2 adhesion resistance to ETEC H10407 and EPEC O119. Caco-2 cells were inoculated in 24-well plates for culture. Caco-2 cells were washed with PBS buffer, and the strains and Caco-2 cells were co-cultured for 1 h. ETEC H10407 and EPEC O119 were added to Caco-2 cells at a multiplicity of infection (MOI) of 50:1 and co-cultured for 1 h (37°C). The final viable count was 1×10 7 CFU / mL. The Caco-2 group without Bifidobacterium BL-99 was used as a negative control. 1mM Zinc Oxide (ZnO) was used instead of Bifidobacterium BL-99 as a positive control group. After incubation, the Caco-2 cells were washed and lysed, and then the pathogens were inoculated on agar. After overnight incubation on agar plates at 37°C, the CFU colonies of bacteria were counted to measure the adsorption of pathogens. The number of growing Escherichia coli colonies was counted and recorded as CFU / mL. In parallel with the anti-adhesion test, Escherichia coli (final concentration) 10 7CFU / mL was added to 1 mL of the test substance (BL-99 bacterial solution) and co-cultured at 37°C for 1 hour to measure activity. After incubation, E. coli were collected from each sample by centrifugation, resuspended in PBS, and plated on agar plates. After incubation on agar plates at 37°C overnight, the CFU colonies of bacteria were counted to measure pathogen adsorption. The number of growing E. coli colonies was counted and recorded as CFU / mL.
[0056] The experiment uses human intestinal cell Caco-2 as a model, and the present invention confirms that Bifidobacterium BL-99 has an inhibitory effect on enterotoxigenic Escherichia coli ETEC H10407 and enteropathogenic Escherichia coli EPEC O119.
[0057] In some batches of experiments of the present invention, 10 8 The experimental results of the inhibitory ability of Bifidobacterium BL-99 on ETEC H10407 at CFU / mL concentration are as follows Figure 2 As shown in Figure 2, without the intervention of Bifidobacterium BL-99, the number of enterotoxigenic Escherichia coli ETEC H10407 adhering to Caco-2 cells was as high as 3.75×10 6 CFU / mL (6.57log CFU / mL). When E. coli ETEC H10407 and Bifidobacterium BL-99 acted together, the number of ETEC H10407 adhered was 7.67×10 5 CFU / mL (5.88 log CFU / mL), and the inhibition rate was 10.8%.
[0058] In some batches of experiments of the present invention, 10 8 The experimental results of the inhibitory ability of Bifidobacterium BL-99 on EPEC O119 at CFU / mL concentration are as follows Figure 3 As shown in Figure 2, without the intervention of Bifidobacterium BL-99, the number of adhesion of enterotoxigenic Escherichia coli ETECH10407 to Caco-2 cells was as high as 2.34×10 6 CFU / mL (6.37log CFU / mL). When E. coli ETEC H10407 and Bifidobacterium BL-99 acted together, the number of ETEC H10407 adhered was 4.5×10 5 CFU / Ml (5.65log CFU / mL), the inhibition rate was 11.29%.
[0059] In other batches of experiments of the present invention, 10 6 CFU / mL and 10 8 CFU / mL of two different concentrations of Bifidobacterium BL-99 for the inhibition of Escherichia coli EPEC O119 adhesion to Caco-2 cells.8 The CFU / mL concentration was determined in two groups. The experimental results (mean ± standard error, repeated three times) are shown in Table 4. After comparing the negative control with the test group using Dunnett's posthoc test, it was found that in experimental group 1, 10 6 The concentration of BL-99 was significantly lower than that of the negative control (P<0.05); 8 The probiotic BL-99 at 10 8 BL-99 at the concentration significantly reduced the adhesion of pathogenic bacteria (P<0.01).
[0060] Table 4
[0061]
[0062]
[0063] The above experimental results show that Bifidobacterium lactis BL-99 has an inhibitory effect on both enterotoxigenic Escherichia coli ETEC H10407 and enteropathogenic Escherichia coli EPEC O119.
[0064] Example 2. Intestinal barrier integrity test
[0065] An ideal intestinal epithelial barrier function is a prerequisite for protecting the host from invading pathogens and / or toxins derived from pathogens. In this study, barrier integrity in vitro was assessed by measuring the transepidermal electrical resistance (TEER) of the intestinal cell layer. To investigate the effect of probiotics on infection, TEER was measured before and after infection with E. coli over time.
[0066] Caco-2 cells were seeded into Transwell polycarbonate cell culture inserts with an average pore size of 0.4 μm and an area of 0.33 cm 2 Until complete differentiation (±1000Ω). The transepithelial electrical resistance (TEER) was measured using an EVOM2 epidermal voltmeter purchased from World Precision Instruments to measure barrier integrity.
[0067] On the day of the test, cells were washed and incubated for 1 hour at 37°C in medium without antibiotics and serum but containing the test substances. E. coli were then added to the test substances (MOI 200:1) and incubated for 6 hours. TEER was measured before the start of the experiment (t=-1), after 1 hour of exposure to the test substances and before the addition of the pathogen (t=0), and at 1 hour, 2 hours, 3 hours, 4 hours and 6 hours after the contact with the pathogen. The TEER values of the individual conditions after contact with the pathogen were related to their respective TEER values at t=0 and expressed as ΔTEER (Ω.Cm2). Negative controls (only E. coli added) and positive controls not exposed to the pathogen or the test substances were also included in the experimental groups. All conditions were measured in triplicate, and some controls were measured in 6 replicates.
[0068] Table 5 records 10 6 The effect of probiotic BL-99 at different CFU / mL concentrations on transmembrane resistance (TEER) when exposed to E. coli ETEC H10407. Table 6 records the effect of probiotic BL-99 at different CFU / mL concentrations on transmembrane resistance (TEER). 8 Effect of probiotic BL-99 at CFU / mL concentration on transmembrane resistance (TEER) when exposed to E. coli ETEC H10407. The experimental data were measured three times.
[0069] Table 5
[0070]
[0071]
[0072] Table 6
[0073]
[0074] 10 6 Compared with the negative control, the Bifidobacterium BL-99 with a CFU / mL concentration showed a tendency to increase the TEER value at time points t=1 and t=2. 8 CFU / mL concentration of Bifidobacterium BL-99 showed a trend of increasing TEER values at multiple time points compared with the negative control.
[0075] Example 3. Immunomodulatory capacity determination
[0076] The immunomodulatory capacity of Bifidobacterium lactis BL-99 was based on the ability to reduce the production of IP-10 (10 kDa interferon-gamma-induced protein, IP10) induced by ETCT H10407 Caco-2 cells. Caco-2 cells were grown to appropriate abundance in 96-well plates. At the beginning of the experiment, the cells were washed once with medium without antibiotics. The monolayers were co-cultured with the test substances in medium without antibiotics at 37 °C for 1 h in triplicate. Escherichia coli was added to stimulate the cells (MOI 200:1). After 1 h of incubation, the monolayers were co-cultured with pathogenic bacteria and washed and incubated overnight with medium containing the test substances and 50 μg / mL gentamicin. As a blank control, only the medium was used without stimulation with E. coli. The medium stimulated with E. coli but without the test substances was used as a control for the E. coli response. In addition, as a control for the response of Caco-2 cells, cells were stimulated with a mixture containing Rec TNFα (10 ng / mL) and Rec IFNγ (5 ng / mL) (both purchased from R&D systems, Abingdon, UK). Supernatants were collected 24 hours after stimulation and stored at -20°C. IP-10 was tested using the Bio-Plex kit (BioRad, California, USA) according to the manufacturer's instructions.
[0077] The experimental results are expressed as mean ± standard deviation; SPSS17.0 software was used for data analysis (SPSS, Chicago, IL, USA), and the significance analysis was performed using the LSD method for one-way analysis of variance. P-value < 0.05 was considered to be statistically significant, and significant differences were distinguished by: *p < 0.05, **p < 0.01, ***p < 0.001. The figures in the article were drawn using GraphPad Prism 5.0.
[0078] 10 8 The results of reducing IP10 production by Bifidobacterium lactis BL-99 at CFU / mL concentration are shown in Figure 4. As shown. The addition of ETEC H10407 to the Caco-2 cell model caused a significant upregulation of IP10, and the IP10 content in the cell culture fluid reached 656.52±57.11pg / mL. The blank group Caco-2 cells were not treated in any way, and the IP10 content in the cell culture supernatant was 162.29±21.28pg / mL. After adding Bifidobacterium BL-99 for 1 hour, the IP10 content in the cell culture supernatant was low, at 146±7.74pg / mL. This shows that Bifidobacterium BL-99 has the ability to inhibit the production of inflammatory factor IP10 and significantly inhibit the inflammatory response caused by ETEC H10407 (p<0.001), further indicating that BL-99 has the potential to reduce the inflammatory response caused by ETEC 10407 to a certain extent.
[0079] Interferon γ-induced protein 10 (IP10) plays an important role in the occurrence and development of UC. IP10 belongs to the ELR-negative CXC subfamily of endogenous chemokines. It is secreted by a variety of cells such as fibroblasts, endothelial cells, monocytes, T lymphocytes, etc. under the induction of IFN-γ. It can also be secreted under the stimulation of lipopolysaccharide, pro-inflammatory factors such as IFN-α / β and TNF-α. CXCR3 is the only receptor for IP10. After IP10 specifically binds to CXCR3, it can promote the chemotactic activity of CXCR3+ cells, thereby triggering a multi-step signal transduction pathway, causing CXCR3-positive target cells such as T cells, B cells, monocytes / macrophages, dendritic cells, NK cells, etc. to chemotaxis toward local inflammatory lesions. Among them, the recruited T cells mainly secrete IL-2, TNF-β, and IFN-γ after activation; macrophages mainly secrete inflammatory factors such as TNF-α, IL-1β, IL-6, IL-18, IL-12, IL-23, and IFN-γ; and the locally increased secretion of inflammatory factors such as TNF-α and IFN-γ, on the one hand, stimulates the production of more IP10, further recruiting more immune cells, forming a vicious circle; on the other hand, it can directly or indirectly damage the intestinal mucosal barrier, thereby damaging the intestinal mucosa and promoting the occurrence and development of ulcerative colitis.
[0080] The above research results confirm that Bifidobacterium lactis BL-99 can significantly reduce the adhesion of ETEC H1407 and EPEC O119 to Caco-2 cells and alleviate the inflammatory response caused by ETEC H10407. This shows that Bifidobacterium lactis BL-99 has good potential for preventing infant diarrhea, traveler's diarrhea, intestinal inflammation, etc.
Claims
1. A use of Bifidobacterium lactis in preparing a composition for improving intestinal immunity, wherein the preservation number of Bifidobacterium lactis is CGMCC No.15650, and the composition for improving intestinal immunity comprises: Improve resistance to intestinal E. coli infection, protect against E. coli invasion in the intestinal system, and / or prevent diarrhea caused by E. coli.
2. The use according to claim 1, wherein: The Bifidobacterium lactis is used to prepare the composition in the form of live bacteria and / or dead bacteria.
3. The use according to claim 1 or 2, wherein: The Bifidobacterium lactis is used to prepare the composition in the form of a solid or liquid bacterial preparation.
4. The use according to claim 1, wherein: The protection against the invasion of E. coli in the intestinal system includes protecting against the invasion of E. coli and / or E. coli-derived toxins by increasing the transepithelial electrical resistance (TEER).
5. The use according to claim 1, wherein: The composition is used for reducing the adhesion ability of Escherichia coli to intestinal epithelial cells and / or reducing the release of inflammatory factor IP-10 by intestinal cells caused by Escherichia coli.
6. The use according to claim 1, wherein: The Escherichia coli includes enterotoxigenic Escherichia coli ETEC H10407 and / or pathogenic Escherichia coli EPEC O119.
7. The use according to any one of claims 1 to 6, wherein: The application amount of Bifidobacterium lactis is 1.0×10 3 CFU~1.0×10 12 CFU / day, or 0.001 μg to 1000 mg / day in terms of bacterial weight.
8. The use according to claim 7, wherein: The application amount of Bifidobacterium lactis is 10 7 CFU~10 11 CFU / day, or 10 μg to 100 mg / day in terms of bacterial weight.
9. The use according to claim 1, wherein: The composition includes a food composition, a feed composition or a pharmaceutical composition.
10. The use according to claim 9, wherein: The food is a liquid beverage, a solid beverage, an oral liquid, a dairy product, a tablet or a capsule.
Citation Information
Patent Citations
Bifidobacterium lactis nbk-W13 and application thereof
CN110452842A
Bifidobacterium bifidum strains for application in gastrointestinal diseases
EP2481299A1
Novel Lactic Acid Bacteria Having Constipation Improvement Effect and Use Thereof
KR1020180044245A
IN709KON2001A
